Penumbra is a medical device company located in California, United States, which is part of the Healthcare sector, and is traded under the ticker PEN on the NYSE exchange.
Penumbra stock last closed at $270.64, down 2.42% from the previous day, and has increased 33.32% in one year. It has overperformed other stocks in the Medical Devices industry by 0.52 percentage points. Penumbra stock is currently +82.86% from its 52-week low of $148.00, and -12.7% from its 52-week high of $310.00.
As of Apr 21, 2025, there are 38.52M shares of PEN outstanding. The market capitalization of PEN is $10.42B. In the last 24 hours, 484,002 PEN shares were traded.
You will need a brokerage account to access the NYSE market and buy PEN stock.
Based on our analysis, eToro is the best stock brokerage. Here's why:
Get $10 towards your purchase of shares by creating an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've selected your brokerage, it's time to fill out some personal details so you can buy PEN stock today.
Now that you have created your account on a investment app, you can securely and quickly fund your account:
Check out the video below to see the process of transferring funds into your brokerage account.
After you have chosen the best place to buy Penumbra stock, it's crucial to evaluate their stock before you buy, so you actually wrap your head around the risk and opportunity.
WallStreetZen was built to help part-time investors do better fundamental analysis in less time.
You can view all of the due diligence checks on PEN's stock page.
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge PEN's intrinsic value.
Using relative valuations metrics:
You can do more valuation research on PEN's stock here.
Out of 13 Equities analysts who give ratings on PEN, the consensus analyst rating on Penumbra is a Strong Buy
Please keep in mind that analyst ratings are not stock recommendations, nor are they financial advice.
Priya Sachdeva, a bottom 32% analyst from UBS maintains PEN with a strong buy rating and raises their PEN price target from $305.00 to $320.00, on Feb 19, 2025.
Larry Biegelsen, a top 14% analyst from Wells Fargo maintains PEN with a strong buy rating and raises their PEN price target from $275.00 to $305.00, on Feb 19, 2025.
Matthew O'Brien, a bottom 3% analyst from Piper Sandler reiterates PEN with a strong buy rating and raises their PEN price target from $250.00 to $330.00, on Feb 19, 2025.
Kallum Titchmarsh, a bottom 31% analyst from Morgan Stanley maintains PEN with a hold rating and raises their PEN price target from $240.00 to $260.00, on Feb 19, 2025.
Richard Newitter, a top 6% analyst from Truist Securities maintains PEN with a strong buy rating and raises their PEN price target from $240.00 to $285.00, on Dec 18, 2024.
Truist Securities's Richard Newitter raised their price target on Penumbra (NYSE: PEN) by 18.8% from $240 to $285 on 2024/12/18. The analyst maintained their Strong Buy rating on the stock.
Newitter raised their price target on Penumbra in a 2025 preview note on names in their MedTech portfolio.
The analyst told readers that Truist Securities views the sector as "one of the better/safer houses" in Healthcare because of its lower "front-line" exposure to healthcare policy rhetoric tied to the administration change, as well as its position as an "innovation segment" with sustainable above-average revenue and EPS growth, strong balance sheets, and healthy free cash flows.
The firm recommends small to midsize companies over large caps because M&A may be "poised to heat up," the analyst added.
You can dig deeper into what analysts are saying on the Penumbra stock forecast page.
Last year, PEN earnings were $14.01M. In the last five year, PEN's earnings have gone up by -23.68% per year. This was slower than the Medical Devices industry average of 10.23%.
Last year, PEN revenue was $1.19B. Over the past five year, PEN's revenue has increased by 16.89% per year. This was faster than the Medical Devices industry average of 9.8%.
Find out more about PEN's earnings and revenue performance here.
Over the last year, executives and large shareholders at PEN have sold more shares than they have bought.
Adam Elsesser, CEO and President of PEN, was the latest PEN insider to buy. They bought $839,280.00 worth of PEN shares on Apr 16, 2025.
Research more about who owns PEN stock here.
No, Penumbra doesn't provide an income stream by paying out dividends.
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other traders have to say.
There are two primary types of orders:
Click the Open Trade button and your broker will place the order.
If you require additional assistance investing in stocks on eToro, click the how to video below:
Now that you own some PEN shares, you'll want to keep up with your investment.
Add PEN to a watchlist to track the most important metrics related to your PEN stock.
To reiterate, here are the 6 steps to buy Penumbra stock:
If you are looking for a brokerage account, eToro is our recommended venue.
Get Started with eToro TodayIf you want to watch your new investment in Penumbra, hit the button below to create your watchlist.